Comparative study between the effect of methotrexate and valproic acid on solid Ehrlich tumour

Journal of the Egyptian National Cancer Institute

Volumn 24, Issue 4, 2012, Pages 161-167

  Abdel Rahman, Mohamed Nabih ^a   Kabel, Ahmed Mohammed ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Ehrlich; Methotrexate; Mice; Valproic

Indexed keywords

CHOLESTEROL; METHOTREXATE; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EHRLICH ASCITES TUMOR; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CATALASE; CHOLESTEROL; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE PEROXIDASE; MALONDIALDEHYDE; METHOTREXATE; MICE; NEOPLASM TRANSPLANTATION; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; VALPROIC ACID;

EID: 84869838588     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2012.08.001     Document Type: Article

References (41)

1. Silva L.A., Nascimento K.A., Maciel M.C., Pinheiro M.T., Sousa P.R., Ferreira S.C., et al. Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice. Chemotherapy 2006, 52:91-94.
2. Sakai M., Ferraz-de-Paula V., Pinheiro M.L., Ribeiro A., Quinteiro-Filho W.M., Rone M.B., et al. Translocator protein (18kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol 2010, 626(2-3):131-138.
3. Mol F., Mol B.W., Ankum W.M., van der Veen F., Hajenius P.J. Current evidence on surgery, systemic MTX and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis" Hum Reprod Update 2008, 14(4):309-319.
4. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Ludviksson B.R., Valdimarsson H. The anti-inflammatory action of MTX is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005, 114:154-163.
5. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35years of clinical experience. CNS Drugs 2002, 16(10):695-714.
6. Sagot-Lerolle N., Lamine A., Chaix M.L., Boufassa F., Aboulker J.P., Costagliola D., et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008, 22(10):1125-1129.
7. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005, 25(4):383-397.
8. Srikanth K., Debnath B., Nayak S.S., Tarun J.H.A. Enhanced regression of tumours in mice with combined chemotherapy & immunotherapy. Indian J Pharmacol 2002, 34:172-177.
9. Basselin M., Chang L., Chen M., Bell J.M., Rapport S. Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats. Neurochem Res 2008, 33(11):2229-2240.
10. Osman A., Sayed-Ahmed M., Khayyal M., El Merzebani M. Hyperthermic potentiation of cisplatin on solid Ehrlich carcinoma. Tumouri 1993, 79:268-272.
11. Attia M., Weiss D.W. Immunology of spontaneous mammary carcinomas in mice infected with mammary tumour virus. Cancer Res 1966, 26:1787-1800.
12. 2). Proc Soc Exp Biol Med 1978, 158:478-481.
13. Uchiyama M., Mihara M. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1979, 86:271-278.
14. Manso C., Wroblewski F. Glutathione reductase activity in blood and body fluids. J Clin Invest 1958, 37:214-218.
15. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973, 19(12):1350-1356.
16. Sarraf C.E., Bowen I.D. Kinetic studies on murine sarcoma and an analysis of apoptosis. Br J Cancer 1988, 54:989-998.
17. Manne U., Weiss H.L., Myers R.B., Danner O.K. Nuclear accumulation of p53 in colorectal adenocarcinomas: prognostic importance differs with race and location of tumour. Cancer 1998, 83:2456-2467.
18. Ozaslan M., Karagoz I.D., Kilic I.H., Guldur M.E. Ehrlich ascites carcinoma. Afr J Biotechnol 2011, 10(13):2375-2378.
19. Segura J.A., Ruiz-Bellido M.A., Arenas M., Lobo C., Marquez J., Alonso F.J. Ehrlich ascites tumor cells expressing anti-sense glutaminase RNA lose their capacity to evade the mouse immune system. Int J Cancer 2001, 91:379-384.
20. Badr El-Din N.K. Protective role of sanumgerman against γ-irradiation-induced oxidative stress in Ehrlich carcinoma-bearing mice. Nutr Res 2004, 24:271-291.
21. Zahran M.A., Salem T.A., Samaka R.M., Agwa H.S., Awad A.R. Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice. Bioorg Med Chem 2008, 16(22):9708-9718.
22. Matés J.M., Segura J.A., Alonso F.J., Márquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 2008, 82(5):273-299.
23. Sarkar S., Yadav P., Bhatnagar D. Effect of cadmium on glutathione metabolism and glucose 6-phosphate dehydrogenase in rat tissues: role of vitamin E and selenium. Trace Elem Electrolytes 1998, 15:101-105.
24. Takahashi H.K., Nishibori M. The antitumour activities of statins. Curr Oncol 2007, 14(6):246-247.
25. Luo J.L., Maeda S., Hsu L.C., Yagita H., Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer cell 2004, 6:297-305.
26. Waterston A., Bower M. TNF and cancer: good or bad?. Cancer Ther 2004, 2:131-148.
27. Ravi R., Zhiquan Z., Lynn M.C., Mary D., Benkovic S.J., Hammes G. Interaction of dihydrofolate reductase with MTX: ensemble and single-molecule kinetics. Proc Natl Acad Sci 2002, 99(21):13481-13486.
28. Basak C., Andeerea K.L., Qing W., Rima R. Methotrexate-induced apoptosis is enhanced by altered expression of methylene tetrahydrofolate reductase. Anti-Cancer Drugs 2009, 20:787-793.
29. Winter-Vann A.M., Kamen B.A., Bergo M.O., Young S.G., Melenyk S., James S.J., et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. PNAS 2003, 100:6234-6529.
30. Sung J.Y., Hong J.H., Kang H.S., Choi I., Lim S.D., Lee J.K., et al. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 2000, 47:35-44.
31. Cutolo M., Sulli A., Pizzorni C., Seriolo B. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001, 60:729-735.
32. Schnyder B, Drexel J, Sauter C. Influence of cyclophosphamide, methotrexate, and 5-fluorouracil on serum cholesterol (Meeting abstract). ASCO Annual Meeting 1996; No. 312.
33. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
34. Cinatl J., Kotchetkov R., Blaheta R., Driever P.H., Vogel J.U., Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 2002, 20:97-106.
35. Fourcade S., Ruiz M., Guilera C., Hahnen E., Brichta L., Naudi A., et al. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 2010, 19(10):2005-2014.
36. Glauben R., Batra A., Fedke I., Zeitz M., Lehr H.A., Leoni F., et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006, 176:5015-5022.
37. Zhang Z., Zhang Z.Y., Fauser U., Schluesener H.J. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008, 65:4055-4065.
38. Zgouras D., Becker U., Loitsch S., Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 2004, 316:693-697.
39. Gurvich N., Tsygankova O.M., Meinkoth J.L., Klein P.S. Histone deacetylase is a target of valproic acidmediated cellular differentiation. Cancer Res 2004, 64:1079-1086.
40. Beger R.D., Hansen D.K., Schnackenberg L.K., Cross B.M., Fatollahi J., Lagunero F.T., et al. Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-13C6]-d-glucose tracer in mice. Metabolomics 2009, 5(3):336-345.
41. Pipalia N.H., Cosner C., Huang A., Chatterjee A., Bourbon P., Farley N., et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. PNAS 2011, 108(14):5620-5625.